• MetXtra™ is a comprehensive technology platform for innovative biocatalysis solutions, combining natural diversity, bioinformatics, and AI to produce efficient enzymes.
• Enzyme identification is tailored to the desired application using BRAIN Biotech's sequence-based and structural bioinformatics and AI tools.
• New enzymes can be designed outside of the natural sequence space using artificial intelligence.
• BRAIN Biotech offers MetXtra™ for establishing and optimizing biocatalytic processes, developing novel enzyme solutions, and generating Intellectual Property (IP) or Free Trade Agreement (FTO).

BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, is pleased to introduce MetXtra™, a comprehensive technology platform that enables innovative solutions for biocatalysis. MetXtra™ was specifically developed by BRAIN Biotech for new and improved enzyme processes to overcome the current limitations of industrial biocatalysis.

Create competitive advantages with MetXtra™ through intelligent combination of nature with bioinformatics and AI
MetXtra™ combines natural diversity, cutting-edge bioinformatics and artificial intelligence to produce unique, highly efficient enzymes. The proprietary MetXtra™ database can be used to identify unique enzymes, as the database contains novel, previously undiscovered and Nagoya-compliant sequences that were created from the fusion of the metagenomic sequence databases of BRAIN Biotech AG and Biocatalysts Ltd. Enzyme identification is tailored precisely to the desired application and uses BRAIN Biotech's wide range of sequence-based and structural bioinformatics and AI tools. In addition, new enzymes can be designed outside of the natural sequence space using artificial intelligence.

Dr. Alexander Pelzer, Vice President and Head of Research at BRAIN Biotech Zwingenberg, explains: "MetXtra offers our customers access to a comprehensive database of previously undiscovered enzymes. The innovative bioinformatics methods enable us to quickly and precisely identify the appropriate enzyme for their specific applications, giving them a significant competitive advantage."

Development and production of novel enzymes in the BRAIN Biotech Group
BRAIN Biotech offers customers access to the MetXtra™ technology platform if they want to establish and optimize biocatalytic processes, develop novel enzyme solutions and generate IP or FTO.

MetXtra™ is fully integrated into the enzyme development pipeline of the BRAIN Biotech Group, which offers excellent enzyme engineering capabilities, access to industrial enzyme production strains and scale-up technologies. In this way, the group enables enzyme solutions from discovery to commercial production.

Download pdf information sheet